GT Biopharma (GTBP) Stock: Buy, Sell, or Hold?
GTBP - GT Biopharma Inc. Common Stock
$6.93
0.13 (1.96%)
â˛
5d:
-3.43%
30d:
+2211.13%
90d:
+1315.85%
WAIT
LOW Confidence
Analysis Updated: Sep 29, 2026 12:00 AM ET
Earnings: Nov 13, 2026
Get Alerted When GTBP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: GTBP is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: GTBP is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: GTBP is currently trading at $6.93, which is considered slightly high relative to its 30-day fair value range of $0.84 to $8.14.
Technical Outlook: Technically, GTBP is in a uptrend. Immediate support is located at $6.33, while resistance sits at $10.48.
Market Sentiment: GTBP scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $75.00 (+1002.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GTBP is in a uptrend. Immediate support is located at $6.33, while resistance sits at $10.48.
Market Sentiment: GTBP scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $75.00 (+1002.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$0.84 -
$8.14
Company Quality Score
31/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
42.1%
All Signals
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 1002.9% below Wall St target ($75.00)
- WARNING: Composite score 31/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.84 -
$8.14
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$6.33
Resistance Level
$10.48
Current Trend
Uptrend
Technical data as of
Sep 28, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.85
Wall Street Target
$75.00
(+1002.9%)
Share & Embed Analysis
Last updated: September 29, 2026 11:31 AM ET
Data refreshes hourly during market hours. Next update: 12:31 PM
Data refreshes hourly during market hours. Next update: 12:31 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GTBP showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 53 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1180 | 64 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$47 | 54 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 45 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$139 | 60 BUY |
